These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 3149884)

  • 41. Mupirocin: a new topical antibiotic.
    Leyden JJ
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):879-83. PubMed ID: 2112165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials.
    Hebert AA; Albareda N; Rosen T; Torrelo A; Grimalt R; Rosenberg N; Zsolt I; Masramon X
    J Drugs Dermatol; 2018 Oct; 17(10):1051-1057. PubMed ID: 30365584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections.
    Gilbert M
    J Am Acad Dermatol; 1989 Jun; 20(6):1083-7. PubMed ID: 2502567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial.
    Bowen AC; Tong SY; Andrews RM; O'Meara IM; McDonald MI; Chatfield MD; Currie BJ; Carapetis JR
    Lancet; 2014 Dec; 384(9960):2132-40. PubMed ID: 25172376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The clinical development of mupirocin.
    Pappa KA
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):873-9. PubMed ID: 2112164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is penicillin still the drug of choice for non-bullous impetigo?
    Feder HM; Abrahamian LM; Grant-Kels JM
    Lancet; 1991 Sep; 338(8770):803-5. PubMed ID: 1681172
    [No Abstract]   [Full Text] [Related]  

  • 47. Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections--an open multicentre trial.
    Bork K; Brauers J; Kresken M
    Br J Clin Pract; 1989 Aug; 43(8):284-8. PubMed ID: 2516463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study.
    Oranje AP; Chosidow O; Sacchidanand S; Todd G; Singh K; Scangarella N; Shawar R; Twynholm M;
    Dermatology; 2007; 215(4):331-40. PubMed ID: 17911992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards evidence based emergency medicine: best BETS from the Manchester Royal Infirmary. Oral or topical antibiotics for impetigo.
    McVicar J
    J Accid Emerg Med; 1999 Sep; 16(5):364-5. PubMed ID: 10505921
    [No Abstract]   [Full Text] [Related]  

  • 50. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
    Rosen T; Albareda N; Rosenberg N; Alonso FG; Roth S; Zsolt I; Hebert AA
    JAMA Dermatol; 2018 Jul; 154(7):806-813. PubMed ID: 29898217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mupirocin (2 percent) ointment in the treatment of primary and secondary skin infections.
    Odom RB
    Cutis; 1989 Jun; 43(6):599-601. PubMed ID: 2501071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mupirocin: a topical antibiotic with a unique structure and mechanism of action.
    Parenti MA; Hatfield SM; Leyden JJ
    Clin Pharm; 1987 Oct; 6(10):761-70. PubMed ID: 3146455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topical Ozenoxacin Cream 1% for Impetigo: A Review.
    Schachner L; Andriessen A; Bhatia N; Grada A; Patele D
    J Drugs Dermatol; 2019 Jul; 18(7):655-661. PubMed ID: 31334625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparative review of current topical antibiotics for impetigo.
    Galindo E; Hebert AA
    Expert Opin Drug Saf; 2021 Jun; 20(6):677-683. PubMed ID: 33726585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial.
    Koning S; van der Wouden JC; Chosidow O; Twynholm M; Singh KP; Scangarella N; Oranje AP
    Br J Dermatol; 2008 May; 158(5):1077-82. PubMed ID: 18341664
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
    Torrelo A; Grimalt R; Masramon X; Albareda López N; Zsolt I
    Dermatology; 2020; 236(3):199-207. PubMed ID: 31958794
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of impetigo: a review.
    Baltimore RS
    Pediatr Infect Dis; 1985; 4(5):597-601. PubMed ID: 4047974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impetigo: a reassessment of etiology and therapy.
    Barton LL; Friedman AD
    Pediatr Dermatol; 1987 Nov; 4(3):185-8. PubMed ID: 3122189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral v topical erythromycin therapies for chlamydial conjunctivitis.
    Patamasucon P; Rettig PJ; Faust KL; Kusmiesz HT; Nelson JD
    Am J Dis Child; 1982 Sep; 136(9):817-21. PubMed ID: 7051813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.